Status:
RECRUITING
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
Lead Sponsor:
Washington University School of Medicine
Collaborating Sponsors:
National Institute of General Medical Sciences (NIGMS)
Conditions:
Pneumonia
Necrotizing Soft Tissue Infection
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Our data suggest that modulating the characteristics of light carries the potential to modify the host response to injury and critical illness and thus, improve outcome. The ability to modify the host...
Detailed Description
The threat of infection is not constant, but rather varies directly with how active we are. This threat is predictable, and for diurnal creatures peaks every 24 hours during the solar day. Not surpris...
Eligibility Criteria
Inclusion
- greater than or equal to 18 years of age and less than or equal to 65 years of age
- one of the following diagnoses requiring inpatient hospital care
- an operation for intraabdominal infection
- an operation for necrotizing soft tissue infection
- an operation for an infected joint
- medical treatment of pneumonia.
Exclusion
- traumatic brain injury
- blindness
- immunocompromised or immunosuppressed state
- infection requiring treatment in preceding 30 days
- blindness
- SARS-CoV-2
Key Trial Info
Start Date :
October 29 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT03482245
Start Date
October 29 2024
End Date
December 31 2026
Last Update
July 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barnes Jewish Hospital
St Louis, Missouri, United States, 63108